

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

FIRST mRNA-LNP-BASED DUAL-TARGET CAR-T CELL INJECTION (SYS6063 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the first mRNA-LNP-based dual-target chimeric antigen receptor (“**CAR**”)-T cell injection (SYS6063 Injection) (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is the world’s first mRNA-LNP-based dual-target cell therapy product approved for clinical trials. By expressing CARs that specifically recognise cluster of differentiation 19 (“**CD19**”) and B-cell maturation antigen (“**BCMA**”), it precisely identifies and eliminates CD19- and BCMA-positive cells in patients to achieve the therapeutic effects. The synergistic effect of the dual targets can eradicate pathogenic cells at their source, fundamentally improving patients’ conditions and addressing the pain points of incurability and high recurrence associated with traditional therapies. Preclinical studies demonstrated that the Product could significantly kill CD19- and BCMA-positive cells, exhibiting a favourable safety and efficacy profile.

The indication for this approved clinical trial is relapsed/refractory systemic lupus erythematosus. Furthermore, the Product has the potential to treat other B-cell/plasma cell-mediated autoimmune diseases, such as myasthenia gravis (MG), rheumatoid arthritis (RA) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, and can also be extended to haematological malignancies including relapsed/refractory multiple myeloma (MM) and B-cell lymphoma, representing high clinical development value. The clinical trial approval of the Product marks another important achievement in the Group's strategic layout in the cell therapy field, laying a solid foundation for the development of cell therapy products including *in vivo*-generated CAR-T products.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 2 June 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.